The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Nanostructured Drug-Global Market Insights and Sales Trends 2025

Nanostructured Drug-Global Market Insights and Sales Trends 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1807687

No of Pages : 122

Ask Your Query
Synopsis
The global Nanostructured Drug market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Nanostructured Drug in various end use industries. The expanding demands from the Cancer and Tumors and Autoimmune Disorders, are propelling Nanostructured Drug market. Liposomes, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Polymeric Micelles segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Nanostructured Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Nanostructured Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Nanostructured Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Nanostructured Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Nanostructured Drug covered in this report include Merck, Pfizer, Novartis, Abbott, GlaxoSmithKline, Roche, Sanofi, Eli Lilly and Astrazeneca, etc.
The global Nanostructured Drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Merck
Pfizer
Novartis
Abbott
GlaxoSmithKline
Roche
Sanofi
Eli Lilly
Astrazeneca
Johnson & Johnson
Celgene
Novavax
Stryker
Gilead Sciences
OSI Pharmaceuticals
Kadmon Pharmaceuticals
Samyang Biopharm
Mitsubishi Pharma
Kaken Pharmaceutical
Selecta Biosciences
Par Pharmaceutical
Cerulean Pharma
Navidea Biopharmaceuticals
Lummy
Global Nanostructured Drug market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Nanostructured Drug market, Segment by Type:
Liposomes
Polymeric Micelles
Solid lipid Nanoparticles
Microemulsion and Nanoemulsion
Nanosuspension
Global Nanostructured Drug market, by Application
Cancer and Tumors
Autoimmune Disorders
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Nanostructured Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Nanostructured Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index
1 Nanostructured Drug Market Overview
1.1 Nanostructured Drug Product Overview
1.2 Nanostructured Drug Market Segment by Type
1.2.1 Liposomes
1.2.2 Polymeric Micelles
1.2.3 Solid lipid Nanoparticles
1.2.4 Microemulsion and Nanoemulsion
1.2.5 Nanosuspension
1.3 Global Nanostructured Drug Market Size by Type
1.3.1 Global Nanostructured Drug Market Size Overview by Type (2018-2029)
1.3.2 Global Nanostructured Drug Historic Market Size Review by Type (2018-2023)
1.3.3 Global Nanostructured Drug Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Nanostructured Drug Sales Breakdown by Type (2018-2023)
1.4.2 Europe Nanostructured Drug Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Nanostructured Drug Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Nanostructured Drug Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Nanostructured Drug Sales Breakdown by Type (2018-2023)
2 Global Nanostructured Drug Market Competition by Company
2.1 Global Top Players by Nanostructured Drug Sales (2018-2023)
2.2 Global Top Players by Nanostructured Drug Revenue (2018-2023)
2.3 Global Top Players by Nanostructured Drug Price (2018-2023)
2.4 Global Top Manufacturers Nanostructured Drug Manufacturing Base Distribution, Sales Area, Product Type
2.5 Nanostructured Drug Market Competitive Situation and Trends
2.5.1 Nanostructured Drug Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Nanostructured Drug Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Nanostructured Drug as of 2022)
2.7 Date of Key Manufacturers Enter into Nanostructured Drug Market
2.8 Key Manufacturers Nanostructured Drug Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Nanostructured Drug Status and Outlook by Region
3.1 Global Nanostructured Drug Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Nanostructured Drug Historic Market Size by Region
3.2.1 Global Nanostructured Drug Sales in Volume by Region (2018-2023)
3.2.2 Global Nanostructured Drug Sales in Value by Region (2018-2023)
3.2.3 Global Nanostructured Drug Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Nanostructured Drug Forecasted Market Size by Region
3.3.1 Global Nanostructured Drug Sales in Volume by Region (2024-2029)
3.3.2 Global Nanostructured Drug Sales in Value by Region (2024-2029)
3.3.3 Global Nanostructured Drug Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Nanostructured Drug by Application
4.1 Nanostructured Drug Market Segment by Application
4.1.1 Cancer and Tumors
4.1.2 Autoimmune Disorders
4.2 Global Nanostructured Drug Market Size by Application
4.2.1 Global Nanostructured Drug Market Size Overview by Application (2018-2029)
4.2.2 Global Nanostructured Drug Historic Market Size Review by Application (2018-2023)
4.2.3 Global Nanostructured Drug Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Nanostructured Drug Sales Breakdown by Application (2018-2023)
4.3.2 Europe Nanostructured Drug Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Nanostructured Drug Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Nanostructured Drug Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Nanostructured Drug Sales Breakdown by Application (2018-2023)
5 North America Nanostructured Drug by Country
5.1 North America Nanostructured Drug Historic Market Size by Country
5.1.1 North America Nanostructured Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Nanostructured Drug Sales in Volume by Country (2018-2023)
5.1.3 North America Nanostructured Drug Sales in Value by Country (2018-2023)
5.2 North America Nanostructured Drug Forecasted Market Size by Country
5.2.1 North America Nanostructured Drug Sales in Volume by Country (2024-2029)
5.2.2 North America Nanostructured Drug Sales in Value by Country (2024-2029)
6 Europe Nanostructured Drug by Country
6.1 Europe Nanostructured Drug Historic Market Size by Country
6.1.1 Europe Nanostructured Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Nanostructured Drug Sales in Volume by Country (2018-2023)
6.1.3 Europe Nanostructured Drug Sales in Value by Country (2018-2023)
6.2 Europe Nanostructured Drug Forecasted Market Size by Country
6.2.1 Europe Nanostructured Drug Sales in Volume by Country (2024-2029)
6.2.2 Europe Nanostructured Drug Sales in Value by Country (2024-2029)
7 Asia-Pacific Nanostructured Drug by Region
7.1 Asia-Pacific Nanostructured Drug Historic Market Size by Region
7.1.1 Asia-Pacific Nanostructured Drug Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Nanostructured Drug Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Nanostructured Drug Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Nanostructured Drug Forecasted Market Size by Region
7.2.1 Asia-Pacific Nanostructured Drug Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Nanostructured Drug Sales in Value by Region (2024-2029)
8 Latin America Nanostructured Drug by Country
8.1 Latin America Nanostructured Drug Historic Market Size by Country
8.1.1 Latin America Nanostructured Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Nanostructured Drug Sales in Volume by Country (2018-2023)
8.1.3 Latin America Nanostructured Drug Sales in Value by Country (2018-2023)
8.2 Latin America Nanostructured Drug Forecasted Market Size by Country
8.2.1 Latin America Nanostructured Drug Sales in Volume by Country (2024-2029)
8.2.2 Latin America Nanostructured Drug Sales in Value by Country (2024-2029)
9 Middle East and Africa Nanostructured Drug by Country
9.1 Middle East and Africa Nanostructured Drug Historic Market Size by Country
9.1.1 Middle East and Africa Nanostructured Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Nanostructured Drug Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Nanostructured Drug Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Nanostructured Drug Forecasted Market Size by Country
9.2.1 Middle East and Africa Nanostructured Drug Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Nanostructured Drug Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Merck
10.1.1 Merck Company Information
10.1.2 Merck Introduction and Business Overview
10.1.3 Merck Nanostructured Drug Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Merck Nanostructured Drug Products Offered
10.1.5 Merck Recent Development
10.2 Pfizer
10.2.1 Pfizer Company Information
10.2.2 Pfizer Introduction and Business Overview
10.2.3 Pfizer Nanostructured Drug Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Pfizer Nanostructured Drug Products Offered
10.2.5 Pfizer Recent Development
10.3 Novartis
10.3.1 Novartis Company Information
10.3.2 Novartis Introduction and Business Overview
10.3.3 Novartis Nanostructured Drug Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Novartis Nanostructured Drug Products Offered
10.3.5 Novartis Recent Development
10.4 Abbott
10.4.1 Abbott Company Information
10.4.2 Abbott Introduction and Business Overview
10.4.3 Abbott Nanostructured Drug Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Abbott Nanostructured Drug Products Offered
10.4.5 Abbott Recent Development
10.5 GlaxoSmithKline
10.5.1 GlaxoSmithKline Company Information
10.5.2 GlaxoSmithKline Introduction and Business Overview
10.5.3 GlaxoSmithKline Nanostructured Drug Sales, Revenue and Gross Margin (2018-2023)
10.5.4 GlaxoSmithKline Nanostructured Drug Products Offered
10.5.5 GlaxoSmithKline Recent Development
10.6 Roche
10.6.1 Roche Company Information
10.6.2 Roche Introduction and Business Overview
10.6.3 Roche Nanostructured Drug Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Roche Nanostructured Drug Products Offered
10.6.5 Roche Recent Development
10.7 Sanofi
10.7.1 Sanofi Company Information
10.7.2 Sanofi Introduction and Business Overview
10.7.3 Sanofi Nanostructured Drug Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Sanofi Nanostructured Drug Products Offered
10.7.5 Sanofi Recent Development
10.8 Eli Lilly
10.8.1 Eli Lilly Company Information
10.8.2 Eli Lilly Introduction and Business Overview
10.8.3 Eli Lilly Nanostructured Drug Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Eli Lilly Nanostructured Drug Products Offered
10.8.5 Eli Lilly Recent Development
10.9 Astrazeneca
10.9.1 Astrazeneca Company Information
10.9.2 Astrazeneca Introduction and Business Overview
10.9.3 Astrazeneca Nanostructured Drug Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Astrazeneca Nanostructured Drug Products Offered
10.9.5 Astrazeneca Recent Development
10.10 Johnson & Johnson
10.10.1 Johnson & Johnson Company Information
10.10.2 Johnson & Johnson Introduction and Business Overview
10.10.3 Johnson & Johnson Nanostructured Drug Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Johnson & Johnson Nanostructured Drug Products Offered
10.10.5 Johnson & Johnson Recent Development
10.11 Celgene
10.11.1 Celgene Company Information
10.11.2 Celgene Introduction and Business Overview
10.11.3 Celgene Nanostructured Drug Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Celgene Nanostructured Drug Products Offered
10.11.5 Celgene Recent Development
10.12 Novavax
10.12.1 Novavax Company Information
10.12.2 Novavax Introduction and Business Overview
10.12.3 Novavax Nanostructured Drug Sales, Revenue and Gross Margin (2018-2023)
10.12.4 Novavax Nanostructured Drug Products Offered
10.12.5 Novavax Recent Development
10.13 Stryker
10.13.1 Stryker Company Information
10.13.2 Stryker Introduction and Business Overview
10.13.3 Stryker Nanostructured Drug Sales, Revenue and Gross Margin (2018-2023)
10.13.4 Stryker Nanostructured Drug Products Offered
10.13.5 Stryker Recent Development
10.14 Gilead Sciences
10.14.1 Gilead Sciences Company Information
10.14.2 Gilead Sciences Introduction and Business Overview
10.14.3 Gilead Sciences Nanostructured Drug Sales, Revenue and Gross Margin (2018-2023)
10.14.4 Gilead Sciences Nanostructured Drug Products Offered
10.14.5 Gilead Sciences Recent Development
10.15 OSI Pharmaceuticals
10.15.1 OSI Pharmaceuticals Company Information
10.15.2 OSI Pharmaceuticals Introduction and Business Overview
10.15.3 OSI Pharmaceuticals Nanostructured Drug Sales, Revenue and Gross Margin (2018-2023)
10.15.4 OSI Pharmaceuticals Nanostructured Drug Products Offered
10.15.5 OSI Pharmaceuticals Recent Development
10.16 Kadmon Pharmaceuticals
10.16.1 Kadmon Pharmaceuticals Company Information
10.16.2 Kadmon Pharmaceuticals Introduction and Business Overview
10.16.3 Kadmon Pharmaceuticals Nanostructured Drug Sales, Revenue and Gross Margin (2018-2023)
10.16.4 Kadmon Pharmaceuticals Nanostructured Drug Products Offered
10.16.5 Kadmon Pharmaceuticals Recent Development
10.17 Samyang Biopharm
10.17.1 Samyang Biopharm Company Information
10.17.2 Samyang Biopharm Introduction and Business Overview
10.17.3 Samyang Biopharm Nanostructured Drug Sales, Revenue and Gross Margin (2018-2023)
10.17.4 Samyang Biopharm Nanostructured Drug Products Offered
10.17.5 Samyang Biopharm Recent Development
10.18 Mitsubishi Pharma
10.18.1 Mitsubishi Pharma Company Information
10.18.2 Mitsubishi Pharma Introduction and Business Overview
10.18.3 Mitsubishi Pharma Nanostructured Drug Sales, Revenue and Gross Margin (2018-2023)
10.18.4 Mitsubishi Pharma Nanostructured Drug Products Offered
10.18.5 Mitsubishi Pharma Recent Development
10.19 Kaken Pharmaceutical
10.19.1 Kaken Pharmaceutical Company Information
10.19.2 Kaken Pharmaceutical Introduction and Business Overview
10.19.3 Kaken Pharmaceutical Nanostructured Drug Sales, Revenue and Gross Margin (2018-2023)
10.19.4 Kaken Pharmaceutical Nanostructured Drug Products Offered
10.19.5 Kaken Pharmaceutical Recent Development
10.20 Selecta Biosciences
10.20.1 Selecta Biosciences Company Information
10.20.2 Selecta Biosciences Introduction and Business Overview
10.20.3 Selecta Biosciences Nanostructured Drug Sales, Revenue and Gross Margin (2018-2023)
10.20.4 Selecta Biosciences Nanostructured Drug Products Offered
10.20.5 Selecta Biosciences Recent Development
10.21 Par Pharmaceutical
10.21.1 Par Pharmaceutical Company Information
10.21.2 Par Pharmaceutical Introduction and Business Overview
10.21.3 Par Pharmaceutical Nanostructured Drug Sales, Revenue and Gross Margin (2018-2023)
10.21.4 Par Pharmaceutical Nanostructured Drug Products Offered
10.21.5 Par Pharmaceutical Recent Development
10.22 Cerulean Pharma
10.22.1 Cerulean Pharma Company Information
10.22.2 Cerulean Pharma Introduction and Business Overview
10.22.3 Cerulean Pharma Nanostructured Drug Sales, Revenue and Gross Margin (2018-2023)
10.22.4 Cerulean Pharma Nanostructured Drug Products Offered
10.22.5 Cerulean Pharma Recent Development
10.23 Navidea Biopharmaceuticals
10.23.1 Navidea Biopharmaceuticals Company Information
10.23.2 Navidea Biopharmaceuticals Introduction and Business Overview
10.23.3 Navidea Biopharmaceuticals Nanostructured Drug Sales, Revenue and Gross Margin (2018-2023)
10.23.4 Navidea Biopharmaceuticals Nanostructured Drug Products Offered
10.23.5 Navidea Biopharmaceuticals Recent Development
10.24 Lummy
10.24.1 Lummy Company Information
10.24.2 Lummy Introduction and Business Overview
10.24.3 Lummy Nanostructured Drug Sales, Revenue and Gross Margin (2018-2023)
10.24.4 Lummy Nanostructured Drug Products Offered
10.24.5 Lummy Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Nanostructured Drug Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Nanostructured Drug Industrial Chain Analysis
11.4 Nanostructured Drug Market Dynamics
11.4.1 Nanostructured Drug Industry Trends
11.4.2 Nanostructured Drug Market Drivers
11.4.3 Nanostructured Drug Market Challenges
11.4.4 Nanostructured Drug Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Nanostructured Drug Distributors
12.3 Nanostructured Drug Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock